ABOUT WPD 101
Indications to treat brain cancers including Glioblastoma.
Cancer cells, including glioblastoma (GBM) tumor cells that are highly resistant to all known therapies, express tumor specific receptors, IL-13RA2 and EphA2 (these receptors are not present in normal cells). ”
This breakthrough solution will be based on the use of therapy targeting IL-13RA2 and EphA2 receptors by genetically modified IL-13 and Ephrin 1 proteins, conjugated to Pseudomonas and Diphtheria bacteria toxins. Recombinant IL-13 and Ephrin 1 proteins armed with potent bacteria toxins preferentially bind to GBM tumor-specific receptors and deliver highly cytotoxic payload. This highly specific targeting of GBM cells will allow for selective elimination of tumor cells by bacteria-toxins-induced cytotoxic effects without affecting normal cells. Furthermore, the planned method of administering the drug to the tumor tissue will be an advantage over standard intravenous administration, resulting in the possible reduction of any potential side effects associated with standard chemotherapy. Development of WPD101 will allow GBM patients access to innovative molecular targeted therapies as an alternative to conventional treatment.
GRANTS / FUNDING
Funding for Phase 1 & 2
In February 2018, an $8 million-dollar grant from the National Centre for Research and Development in Poland for the development of WPD101 that would include Phase I clinical studies in GBM tumors
WPD101 has not been submitted for FDA or EMA approval so far
PARTNERS, AFFILIATIONS & LICENSE
Wake Forest Baptist Medical Center
Recognized, fully integrated academic medical center and health system located in Winston-Salem, North Carolina, USA
North Carolina Baptist Hospital
Operates inpatient hospitals, community health centers, health maintenance organization, primary care centers and teaching hospital as a subsidiary of Wake Forest Baptist Medical Center
WPD101 is currently in preclinical development and its consistent anticancer properties are demonstrated and validated in dogs with spontaneous GBM closely resembling GBM in human patients. Overall, results of these studies indicate the significant potential of WPD101 demonstrating the same effective treatment of GBM in humans. Phase I of clinical trial is expected to begin in 2020.
Primary focus on GBM and subsequently on other cancers with similarly high overexpression of IL-13RA2 and EphA2 receptors (for example uveal melanoma).
In addition to GBM, it is known that uveal melanoma cancer cells also express a high level of IL-13RA2 receptors. WPD Pharmaceuticals is going to develop WPD101 therapy in a uveal melanoma model, the localization of which allows local drug administration.
- choosing a selection results in a full page refresh
- press the space key then arrow keys to make a selection